Tools
Stock profile

Vericel Corp (VCEL)

VCEL · Latest close $58.65 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$58.65
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

Vericel Corp (VCEL) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Insiders were net sellers over the last 90 days ($0 bought vs $5.9M sold). Latest close $58.65 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-5.9M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Mairs & Power Funds — 1 tracked fund hold VCEL. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 16 sales ($5.9M). Insider trading

Often held alongside

AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Mairs & Power Funds0.01%25,865HELD Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +28.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

61.8028.042024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding316 of 8,857 filers
Long-only filers among them316
Change vs 2026 Q1+45 net · 304 entered · 259 exited
Shares reported, all filers55,277,493
Reported value, all filers$2.4B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$276.3M
Net income · FY2025$16.5M
Total assets · FY2025$488.0M
Shares outstanding51,206,614
Market cap (at latest close)$3.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 24, 2026.

Short interest

Shares short · Oct 15, 20265,238,041
Share of shares outstanding10.23%
Days to cover9.52

Shares short at recent settlements — Jul 31, 2026: 4.4M · Aug 14, 2026: 4.7M · Aug 31, 2026: 4.8M · Sep 15, 2026: 5.5M · Sep 30, 2026: 5.2M · Oct 15, 2026: 5.2M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 24, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 783 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 24, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 16 sales by 5 insiders ($5.9M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 13, 2026SIEGAL JONATHANPrincipal Accounting OfficerSell263$57.78$15.2KSEC filing
Nov 13, 2026SIEGAL JONATHANPrincipal Accounting OfficerSell935$57.62$53.9KSEC filing
Nov 13, 2026SIEGAL JONATHANPrincipal Accounting OfficerSell687$57.80$39.7KSEC filing
Nov 11, 2026Mara Joseph Anthony JrChief Financial OfficerSell8$59.75$478SEC filing
Nov 10, 2026MCLAUGHLIN KEVIN FSell7,000$58.96$412.7KSEC filing
Nov 9, 2026Mara Joseph Anthony JrChief Financial OfficerSell25,000$58.26$1.5MSEC filing
Nov 9, 2026ZERBE ROBERT L MDSell2,000$57.88$115.8KSEC filing
Nov 6, 2026Mara Joseph Anthony JrChief Financial OfficerSell14,068$53.41$751.4KSEC filing
Nov 6, 2026Mara Joseph Anthony JrChief Financial OfficerSell14,573$53.43$778.6KSEC filing
Nov 5, 2026Mara Joseph Anthony JrChief Financial OfficerSell10,932$53.40$583.8KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 12, 2026MCLAUGHLIN KEVIN FDirector7,000$308.8KAug 12, 2026SEC filing
Aug 3, 2026Halpin MichaelOfficer10,000$459.8KAug 3, 2026SEC filing
Jul 30, 2026SIEGAL JONATHANOfficer4,500$220.1KJul 30, 2026SEC filing
Jun 26, 2026Flynn Sean C.Officer15,000$684.7KJun 26, 2026SEC filing
Jun 26, 2026Mara Joseph Anthony JrOfficer5,000$223.8KJun 26, 2026SEC filing
Jun 26, 2026SIEGAL JONATHANOfficer2,732$122.7KJun 26, 2026SEC filing
Jun 26, 2026Hopper Jonathan MarkOfficer10,000$450.0KJun 26, 2026SEC filing
Jun 18, 2026Flynn Sean C.Officer15,000$603.1KJun 18, 2026SEC filing
Jun 18, 2026Halpin MichaelOfficer10,000$402.4KJun 18, 2026SEC filing
Jun 2, 2026Hopper Jonathan MarkOfficer4,375$153.1KJun 2, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 13, 2026Soleus Capital Master Fund, L.P.SC 13G/A1,458,8822.8%Jun 30, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G2,603,1285.1%Mar 31, 2026SEC filing
Apr 1, 2026Soleus Capital Master Fund, L.P.SC 13G2,549,0795.0%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Nov 12, 2025Brown Capital Management, LLCSC 13G/A1,950,9893.9%Sep 30, 2025SEC filing
Nov 10, 2025STATE STREET CORPORATIONSC 13G2,807,2425.6%Sep 30, 2025SEC filing
May 15, 2025Brown Capital Management, LLCSC 13G/A3,235,7316.6%Dec 31, 2024SEC filing
Apr 30, 2025BlackRock, Inc.SC 13G/A7,570,28015.1%Mar 31, 2025SEC filing
Feb 14, 2025Brown Capital Management, LLCSC 13G/A3,235,7316.6%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).

Federal contracts: $37.8M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$503.1K
FY2022$707.2K
FY2023$257.6K
FY2024$441.5K
FY2025$350.5K
FY2026$35.5M

Largest awards collected

Award IDAgencyAmountStart
75A50126C00002Department of Health and Human Services$34.9MApr 1, 2026
36C24626P0844Department of Veterans Affairs$152.8KJul 16, 2026
36C24622P0664Department of Veterans Affairs$111.2KMar 7, 2022
36C24126P0834Department of Veterans Affairs$76.4KSep 30, 2026
36C24126P0827Department of Veterans Affairs$76.4KSep 29, 2026

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Piotroski — Financial health improved over the past year

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Growth — Latest revenue: $276.3M · 5-yr revenue CAGR: 17.8% · Straight growth years: 9

· Piotroski — F-score: 8 · Return on assets: 3.4% · Operating cash flow: $51.9M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold VCEL — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 30, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
May 18, 20265.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on VCEL

One email a week: the week’s new filings and research. Subscribe free

← VB  ·  VCTR →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.